The study was aimed at the evaluation of blood platelet activation and reactivity in patients in the convalescent phase of stroke (n=58) and controls matched in respect to risk factors of vascular pathology (n=55). Both groups were treated daily with acetylsalicylic acid (ASA), 150 mg/day. Using flow cytometry, the expressions of P-selectin and the active GP IIb/IIIa receptor, as well as the fraction of platelet-derived microparticles (PMPs) and total platelet aggregates (Ag), were evaluated in non-stimulated platelets and in platelets stimulated in vitro by thrombin, thrombin receptor activating peptide (TRAP) or ADP. The expression of P-selectin in non-stimulated platelets was found to be significantly (p=0.04) lower in stroke patients. In parallel, these patients manifested a significantly (p=0.0008) higher proportion of PMPs and a lowered (p=0.003) proportion of Ag, as compared to the controls. In the stroke patients the increased expressions of P-selectin and active GP IIb/IIIa in TRAP- or ADP-activated cells were less pronounced (p<0.01), while the increments in PMP fraction remained higher (p<0.05). Our results may indicate that chronic platelet activation develops in patients in the convalescent phase of stroke and the process of PMP generation prevails over blood platelet degranulation and aggregation. This shift may be particularly unfavourable due to the procoagulative and proatherosclerotic properties of PMPs, accompanied by their decreased sensitivity to the action of antiplatelet drugs.
Note: The results of this study were presented in part during a poster session at the XVIII European Stroke Conference in Stockholm, 26–29 May 2009.
1
Lev EI,
Alviar CL,
Arikan ME.
et al.
Platelet reactivity in patients with subacute stent thrombosis compared with non-stent-related acute myocardial infarction. Am Heart J 2007; 153: 41-46.
2
Choudhury A,
Chung I,
Blann AD.
et al.
Platelet surface CD62P and CD63, mean platelet volume, and soluble/platelet P-selectin as indexes of platelet function in atrial fibrillation: a comparison of ׳healthy control subjects׳ and ׳disease control subjects׳ in sinus rhythm. J Am Coll Cardiol 2007; 49: 1957-1964.
4
Nomura S,
Kanazawa S,
Fukuhara S.
Effects of efonidipine on platelet and monocyte activation markers in hypertensive patients with and without type 2 diabetes mellitus. J Hum Hypertens 2002; 16: 539-547.
6
de Man FH,
Nieuwland R,
van der Laarse A.
et al.
Activated platelets in patients with severe hypertriglyceridemia: effects of triglyceride-lowering therapy. Atherosclerosis 2000; 152: 407-414.
7
Joseph EJ,
Harrison P,
Mackie IJ.
et al.
Increased circulating platelet-leukocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. Br J Haematol 2001; 115: 451-459.
8
Cha JK,
Jeong MH,
Jang JY.
et al.
Serial measurement of surface expressions of CD63, P-selectin and CD40 ligand on platelets in atherosclerotic ischemic stroke. A possible role of CD40 ligand on platelets in atherosclerotic ischemic stroke. Cerebrovasc Dis 2003; 16: 376-382.
9
Schmitz G,
Rothe G,
Ruf A.
et al.
European Working Group on Clinical Cell Analysis: Consensus protocol for the flow cytometric characterisation of platelet function. Thromb Haemost 1998; 79: 885-896.
10
Michelson AD,
Barnard MR,
Krueger LA.
et al.
Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001; 104: 1533-1537.
11
Garlichs CD,
Kozina S,
Fateh-Moghadam S.
et al.
Upregulation of CD40-CD40 ligand (CD154) in patients with acute cerebral ischemia. Stroke 2003; 34: 1412-1418.
12
Jennings LK.
Mechanisms of platelet activation: Need for new strategies to protect against platelet-mediated atherothrombosis. Thromb Haemost 2009; 102: 248-257.
14
Grau AJ,
Ruf A,
Vogt A.
et al.
Increased fraction of circulating activated platelets in acute and previous cerebrovascular ischemia. Thromb Haemost 1998; 80: 298-301.
17
Yip HK,
Chen SS,
Liu JS.
et al.
Serial changes in platelet activation in patients after ischemic stroke: role of pharmacodynamic modulation. Stroke 2004; 35: 1683-1687.
18
McCabe DJH,
Harrison P,
Mackie IJ.
et al.
Platelet degranulation and monocyte-platelet complex formation are increased in the acute and convalescent phases after ischaemic stroke or transient ischaemic attack. Br J Haematol 2004; 125: 777-787.
19
Yamazaki M,
Uchiyama S,
Iwata M.
Measurement of platelet fibrinogen binding and p-selectin expression by flow cytometry in patients with cerebral infarction. Thromb Res 2001; 104: 197-205.
20
Serebruany VL,
Malinin AI,
Oshrine BR.
et al.
Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy. Thromb Res 2004; 113: 197-204.
21
Grau AJ,
Reiners S,
Lichy C.
et al.
Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study. Stroke 2003; 34: 849-854.
22
Bamford J,
Sandercock P,
Dennis M.
et al.
Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991; 337: 1521-1526.
24
Watala C,
Boncler M,
Golanski J.
et al.
Release of calcium and P-selectin from intraplatelet granules is hampered by procaine. Thromb Res 1999; 94: 1-11.
25
Watala C,
Golanski J,
Boncler MA.
et al.
Membrane lipid fluidity of blood platelets: a common denominator that underlies the opposing actions of various agents that affect platelet activation in whole blood. Platelets 1998; 9: 315-327.
26
Yano Y,
Kambayashi J,
Shiba E.
et al.
The role of protein phosphorylation and cytoskeletal reorganization in microparticle formation from the platelet plasma membrane. Biochem J 1994; 299: 303-308.
30
Matzdorff AC,
Kuhnel G,
Kemkes-Matthes B.
et al.
Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates and microparticles in vitro. J Lab Clin Med 2000; 135: 247-255.
34
Sinauridze EI,
Kireev DA,
Popenko NY.
et al.
Platelet microparticle membranes have 50– to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost 2007; 97: 119-123.
